Autolus Q2 Revenue Hits ~$45M, Raises FY Guidance to $150M, Secures $250M Credit Line
AUTL sits 42% above its 52-week low of $1.175.
Summary
Autolus reported preliminary Q2 2026 net product revenue of about $45 million, a sharp sequential jump from Q1's $26.2 million. The company raised its full-year 2026 sales guidance to $140–$150 million, signaling accelerating commercial traction for Aucatzyl. A new credit facility of up to $250 million with Perceptive Advisors provides additional financial flexibility. This follows the strong Q1 results and manufacturing agreement announced in May, reinforcing the revenue ramp. The raised guidance and large credit line suggest management sees sustained demand and is positioning for further growth.
At the time of this announcement, AUTL was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $396.6M. The 52-week trading range was $1.18 to $2.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.